CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
PP 1420 +1 moredrug
Likely dose
PP 1420 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01052493
NCT01052493Phase 1Completed
CompareCT.gov

A First Time in Human, Double Blind, Randomised, Placebo Controlled Dose Escalation Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects.

Imperial College London·interventional·Posted Jan 20, 2010·Updated Feb 12, 2021

In Brief

A Phase 1 clinical trial evaluating PP 1420 and Placebo for Obesity. Completed, enrolled 13 participants across 1 site.

Detailed Summary

When humans eat, the bowels naturally secrete chemicals into the bloodstream which make people feel full and which stop eating. One of these chemicals is known as "Pancreatic Polypeptide" (PP). We have previously shown that injections of human PP reduces appetite and food intake. We have now developed a very similar chemical, PP 1420, as a treatment for obesity. PP 1420 has been tested in animals and has been shown to be safe, and to reduce their appetite. This study will test PP 1420 for its safety and tolerability in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited Kingdom
CollaboratorsWellcome Trust, Imperial College Healthcare NHS Trust

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 20, 2010
Enrollment StartApr 1, 2010
Primary CompletionOct 18, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.4 years ago

Interventions

PP 1420drug

Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.

Placebodrug

0.9% saline